🔍
Showing 503 articles
← Return to All Dispatches / Health & Medicine
#584 Health & Medicine

Human Protein Galectin-3 Blocks Dengue Virus Entry and Boosts Innate Immune Signaling

Health & Medicine • Epidemiology • Public Health

A new study published in Virology Journal shows that galectin-3—a naturally occurring human sugar-binding protein—acts as a built-in defense factor against dengue virus by latching onto sugar chains on the virus's outer shell and amplifying early immune warning signals [1, 2]. Led by researchers Zhi-Sheng Yang, Sheng-Fan Wang, and colleagues, the work demonstrates that extracellular galectin-3 dose-dependently reduces Dengue virus serotype 2 (DENV-2) infectivity while boosting pro-inflammatory NF-κB signaling inside host cells [1, 2].

Dengue virus infects tens of millions of people each year across tropical and subtropical regions, yet no widely effective direct-acting antiviral drug is currently approved for clinical treatment [3]. Understanding how human host proteins naturally slow the virus down offers a promising blueprint for host-directed therapies that strengthen the body's own defenses [1, 3].

How Galectin-3 Blocks Viral Entry

To infect a human cell, dengue virus relies on its outer envelope (E) glycoprotein—a surface protein studded with branching sugar molecules called glycans—to attach to receptors on the cell membrane [1]. Galectin-3 belongs to a family of immune proteins known as lectins, which specialize in recognizing and binding specific carbohydrate structures [1].

Using cell-culture assays and biochemical binding experiments, the researchers found that galectin-3 binds directly to glycan structures on the DENV-2 envelope glycoprotein, including interactions involving the Asn67 glycosylation site [1, 2]. Once galectin-3 coats those viral surface sugars, the virus can no longer attach efficiently to host cells or complete entry, sharply lowering the number of new infectious viral particles produced [1].

Host–Pathogen Mechanism Observed Experimental Effect Biological Outcome
Extracellular Galectin-3 Dose-dependent drop in DENV-2 infectivity Fewer infectious viral progeny released [1]
Envelope Glycan Binding Targets E-protein sugar chains (including Asn67) Physically blocks viral attachment and cell entry [1, 2]
NF-κB Immune Signaling Upregulates IL-6, IL-8, and TNF cytokines Accelerates early innate antiviral immune alert [1, 2]
Galectin-3 Deficiency / Suppression DENV-2 lowers endogenous galectin-3; loss worsens disease Highlights role as a natural host restriction factor [1, 2]

Dual Action: Physical Shielding and Immune Alarm

Galectin-3 does more than act as a molecular shield outside the cell [1]. The study shows that galectin-3 also enhances NF-κB signaling—a central cellular switch that turns on genes involved in inflammation and antiviral defense [1, 2]. When galectin-3 is present during DENV-2 exposure, cells upregulate key immune signaling molecules, including interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor (TNF), helping recruit and activate immune responses against the invading virus [1].

Interestingly, the researchers also observed a biological tug-of-war between the virus and the host [1]. Active DENV-2 infection tends to drive down the host's own endogenous galectin-3 levels, whereas animal and cell-culture models lacking galectin-3 experience more severe viral infection [1, 2]. Together, those findings indicate that suppressing galectin-3 helps the virus gain a foothold, while restoring or supplementing it tilts the balance back toward host protection [1].

Implications for Host-Directed Dengue Therapies

Because dengue virus exists as four distinct serotypes and evolves rapidly under immune pressure, drugs that target viral enzymes directly can face resistance hurdles [3]. By contrast, targeting conserved structural features such as envelope glycans—or boosting natural host restriction factors like galectin-3—could offer broader protection across viral variants [1, 3].

The authors note that careful preclinical work will be needed before translating galectin-3 biology into treatments, particularly because excessive pro-inflammatory cytokine signaling can contribute to severe dengue symptoms if not tightly controlled [1, 3]. Even so, identifying galectin-3 as a dual-acting restriction factor that both blocks viral entry and primes innate immunity adds an important piece to the puzzle of human defense against mosquito-borne flaviviruses [1, 2].

References & Primary Sources

  1. [1] Yang, Z.-S., Hsu, Y.-T., Baua, A. D., Chen, P.-C., Assavalapsakul, W., Thitithanyanont, A., Wang, W.-H., Lin, C.-Y., Chao, D.-Y., Chen, Y.-H., & Wang, S.-F. (2026). Galectin-3 restricts dengue virus infection through glycan-dependent envelope binding and enhances NF-κB signaling. Virology Journal. — https://doi.org/10.1186/s12985-026-03362-4
  2. [2] Bioengineer.org (2026). Galectin-3 Restricts Dengue Virus Infection Through Envelope Binding and Immune Signaling. — https://bioengineer.org/galectin-3-restricts-dengue-virus-infection-through-envelope-binding-and-immune-signaling/
  3. [3] World Health Organization (WHO). Dengue and Severe Dengue Fact Sheet. — https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue